MX384964B - Células t modificadas en receptor de antígeno quimérico dirigo a cs1. - Google Patents

Células t modificadas en receptor de antígeno quimérico dirigo a cs1.

Info

Publication number
MX384964B
MX384964B MX2017007250A MX2017007250A MX384964B MX 384964 B MX384964 B MX 384964B MX 2017007250 A MX2017007250 A MX 2017007250A MX 2017007250 A MX2017007250 A MX 2017007250A MX 384964 B MX384964 B MX 384964B
Authority
MX
Mexico
Prior art keywords
chimeric antigen
cells
antigen receptor
receptor modified
directed chimeric
Prior art date
Application number
MX2017007250A
Other languages
English (en)
Spanish (es)
Other versions
MX2017007250A (es
Inventor
Stephen J Forman
Xiuli Wang
Original Assignee
Hope City
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hope City filed Critical Hope City
Publication of MX2017007250A publication Critical patent/MX2017007250A/es
Publication of MX384964B publication Critical patent/MX384964B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2017007250A 2014-12-05 2015-12-07 Células t modificadas en receptor de antígeno quimérico dirigo a cs1. MX384964B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462088423P 2014-12-05 2014-12-05
PCT/US2015/064303 WO2016090369A1 (en) 2014-12-05 2015-12-07 Cs1 targeted chimeric antigen receptor-modified t cells

Publications (2)

Publication Number Publication Date
MX2017007250A MX2017007250A (es) 2018-02-16
MX384964B true MX384964B (es) 2025-03-11

Family

ID=55069093

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017007250A MX384964B (es) 2014-12-05 2015-12-07 Células t modificadas en receptor de antígeno quimérico dirigo a cs1.
MX2021008498A MX2021008498A (es) 2014-12-05 2017-06-05 Celulas t modificadas en receptor de antigeno quimerico dirigo a cs1.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021008498A MX2021008498A (es) 2014-12-05 2017-06-05 Celulas t modificadas en receptor de antigeno quimerico dirigo a cs1.

Country Status (12)

Country Link
US (3) US10821161B2 (Direct)
EP (2) EP3227315B1 (Direct)
JP (2) JP7098325B2 (Direct)
KR (1) KR102558502B1 (Direct)
CN (2) CN114085856A (Direct)
AU (2) AU2015357485B2 (Direct)
BR (1) BR112017011893A2 (Direct)
CA (1) CA2969704C (Direct)
IL (3) IL290459B2 (Direct)
MX (2) MX384964B (Direct)
RU (1) RU2727451C2 (Direct)
WO (1) WO2016090369A1 (Direct)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2776698T3 (es) 2012-12-20 2020-07-31 Purdue Research Foundation Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
BR112016024579A2 (pt) 2014-04-23 2017-10-10 Juno Therapeutics Inc métodos para isolamento, cultura e engenharia genética de populações de célula imune para terapia adotiva
BR112017011893A2 (pt) 2014-12-05 2018-07-24 City Of Hope células t modificadas no receptor de antígeno quimérico direcionado para cs1
AU2016212158B2 (en) 2015-01-26 2021-06-03 Allogene Therapeutics, Inc. mAb-driven chimeric antigen receptor systems for sorting/depleting engineered immune cells
ES2848478T3 (es) 2015-09-11 2021-08-09 Biosceptre Uk Ltd Receptores quiméricos para antígenos y usos de estos
WO2017130223A2 (en) 2016-01-29 2017-08-03 Virocan Therapeutics Pvt. Ltd. A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
KR102120815B1 (ko) 2016-04-01 2020-06-12 카이트 파마 인코포레이티드 키메라 수용체 및 그의 사용 방법
PE20190120A1 (es) 2016-04-01 2019-01-17 Kite Pharma Inc Moleculas de union a bcma y metodos de uso de las mismas
WO2017173256A1 (en) 2016-04-01 2017-10-05 Kite Pharma, Inc. Chimeric antigen and t cell receptors and methods of use
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
JP7175769B2 (ja) * 2016-06-30 2022-11-21 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 改善された養子ｔ細胞療法
CN105949324B (zh) * 2016-06-30 2019-08-27 上海恒润达生生物科技有限公司 靶向gpc3的嵌合抗原受体及其用途
EP3518944A4 (en) * 2016-09-30 2020-06-17 Baylor College of Medicine ADAPTIVE CHIMERIC ANTIGENT RECEPTOR T-CELL DESIGN
WO2018156711A1 (en) * 2017-02-22 2018-08-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Il13ra2-binding chimeric antigen receptors
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
WO2018169922A2 (en) 2017-03-13 2018-09-20 Kite Pharma, Inc. Chimeric antigen receptors for melanoma and uses thereof
CN110636849A (zh) * 2017-03-20 2019-12-31 希望之城公司 用于治疗al淀粉样变的经cs1靶向性嵌合抗原受体修饰的t细胞
BR112019020168A2 (pt) 2017-03-27 2020-06-02 F. Hoffmann-La Roche Ag Receptores de ligação ao antígeno, células t transduzidas, polinucleotídeo isolado, vetor, kits, métodos para tratar uma doença e para induzir a lise de uma célula alvo e uso do receptor de ligação ao antígeno
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
WO2018197675A1 (en) * 2017-04-28 2018-11-01 Julius-Maximilians-Universität Würzburg Ror1-specific chimeric antigen receptors (car) with humanized targeting domains
CA3071303A1 (en) * 2017-08-01 2019-02-07 Julius-Maximilians-Universitat Wurzburg Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemia
EP3666032B1 (en) 2017-08-11 2026-02-11 InterDigital Patent Holdings, Inc. Traffic steering and switching between multiple access networks
US12258580B2 (en) * 2017-11-01 2025-03-25 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
WO2019099433A2 (en) * 2017-11-14 2019-05-23 Arcellx, Inc. D-domain containing polypeptides and uses thereof
EP3710471A1 (en) 2017-11-16 2020-09-23 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
CA3089051A1 (en) 2018-01-22 2019-07-25 Endocyte, Inc. Methods of use for car t cells
SG11202007513PA (en) 2018-02-16 2020-09-29 Kite Pharma Inc Modified pluripotent stem cells and methods of making and use
US12240870B2 (en) 2018-02-23 2025-03-04 Purdue Research Foundation Sequencing method for CAR T cell therapy
CN112166193A (zh) * 2018-05-21 2021-01-01 生物权威（英国）有限公司 具有经修饰的接头结构域的嵌合抗原受体及其用途
WO2020009868A1 (en) * 2018-07-03 2020-01-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-slamf7 chimeric antigen receptors
US12281152B2 (en) 2018-08-01 2025-04-22 City Of Hope TAG72 targeted chimeric antigen receptor modified T cells for treatment of TAG72-positive tumors
CN112469734A (zh) * 2018-08-03 2021-03-09 南京驯鹿医疗技术有限公司 表达嵌合抗原受体的t细胞、该嵌合抗原相关表达载体以及它们的应用
IL280659B2 (en) 2018-08-09 2024-11-01 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
IL316392A (en) 2018-12-12 2024-12-01 Kite Pharma Inc Chimeric antigen receptors and CAR-T cells and methods of use
WO2020206248A1 (en) 2019-04-03 2020-10-08 Precision Biosciences, Inc. Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
WO2020243007A1 (en) * 2019-05-24 2020-12-03 City Of Hope Ccr4 targeted chimeric antigen receptor modified t cells for treatment of ccr4 positive malignancies
CA3143108A1 (en) * 2019-06-19 2020-12-24 Julius-Maximilians-Universitat Wurzburg Ultramodular igg3-based spacer domain and multi-function site for implementation in chimeric antigen receptor design
CN112442126B (zh) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞
JP2023525049A (ja) * 2020-05-08 2023-06-14 シアトル・チルドレンズ・ホスピタル・ドゥーイング／ビジネス／アズ・シアトル・チルドレンズ・リサーチ・インスティテュート ナチュラルキラー細胞を標的とするキメラ抗原受容体（ｃａｒ）
WO2021242719A1 (en) * 2020-05-27 2021-12-02 The Medical College Of Wisconsin, Inc. Improved lentiviral vector transfer plasmid and methods of use
WO2022031602A1 (en) * 2020-08-06 2022-02-10 Promab Biotechnologies, Inc. Cs1- antibody and anti-cs1-car-t cells
EP4192873A1 (en) * 2020-08-10 2023-06-14 Julius-Maximilians-Universität Würzburg Siglec-6-binding polypeptides
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CN117083292A (zh) * 2021-04-02 2023-11-17 科济生物医药（上海）有限公司 Cs1工程化细胞及其组合物
WO2023107898A1 (en) * 2021-12-06 2023-06-15 The Children's Hospital Of Philadelphia Dual targeting of pediatric malignancies through car t-cells secreting bispecific innate immune cell engagers (bices)
CN116410331B (zh) * 2021-12-31 2024-01-30 合源生物科技(天津)有限公司 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用
EP4499230A1 (en) * 2022-03-25 2025-02-05 F. Hoffmann-La Roche AG Improved chimeric receptors
WO2024114691A1 (en) * 2022-12-02 2024-06-06 Guangzhou Litai Biotechnology Co., Ltd. Human cs1 car-t cells
CN119019554B (zh) * 2023-05-25 2025-08-12 东莞市朋志生物科技有限公司 抗白介素6抗体、检测白介素6的试剂和试剂盒

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002063A1 (en) 1989-08-11 1991-02-21 Amrad Corporation Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
WO2007047829A2 (en) 2005-10-19 2007-04-26 Laboratoires Serono S.A. Novel heterodimeric proteins and uses thereof
GB0523954D0 (en) * 2005-11-24 2006-01-04 Ucb Celltech Bioassays
MX363905B (es) * 2006-06-12 2019-04-08 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
WO2011100566A2 (en) 2010-02-12 2011-08-18 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
CA3116051C (en) 2012-03-23 2023-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
AU2013243861A1 (en) 2012-04-05 2014-10-23 Ac Immune S.A. Humanized Tau antibody
US10358494B2 (en) 2013-05-03 2019-07-23 Ohio State Innovation Foundation CS1-specific chimeric antigen receptor engineered immune effector cells
US20160333108A1 (en) * 2014-01-13 2016-11-17 Stephen J. Forman CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
PL3105317T3 (pl) 2014-02-14 2019-02-28 Cellectis Komórki do immunoterapii zaprojektowane do celowania antygenu obecnego zarówno na komórkach odpornościowych, jak i komórkach patologicznych
EP3137498A1 (en) * 2014-05-02 2017-03-08 Cellectis Cs1 specific multi-chain chimeric antigen receptor
BR112017011893A2 (pt) * 2014-12-05 2018-07-24 City Of Hope células t modificadas no receptor de antígeno quimérico direcionado para cs1
CN110636849A (zh) * 2017-03-20 2019-12-31 希望之城公司 用于治疗al淀粉样变的经cs1靶向性嵌合抗原受体修饰的t细胞

Also Published As

Publication number Publication date
AU2015357485A1 (en) 2017-06-29
IL290459B1 (en) 2023-07-01
JP7098325B2 (ja) 2022-07-11
IL280917B (en) 2022-03-01
US20240009288A1 (en) 2024-01-11
MX2021008498A (es) 2021-08-19
JP7252379B2 (ja) 2023-04-04
HK1247642A1 (zh) 2018-09-28
CN107429253B (zh) 2021-11-05
US20210170001A1 (en) 2021-06-10
IL252645A0 (en) 2017-07-31
IL290459A (en) 2022-04-01
AU2021200122B2 (en) 2023-02-23
IL252645B (en) 2021-03-25
US20170360910A1 (en) 2017-12-21
CN107429253A (zh) 2017-12-01
CA2969704A1 (en) 2016-06-09
WO2016090369A1 (en) 2016-06-09
EP3227315A1 (en) 2017-10-11
BR112017011893A2 (pt) 2018-07-24
JP2022051744A (ja) 2022-04-01
EP3227315B1 (en) 2022-11-23
US11730797B2 (en) 2023-08-22
RU2017121826A (ru) 2019-01-10
IL280917A (en) 2021-04-29
RU2017121826A3 (Direct) 2019-07-17
KR102558502B1 (ko) 2023-07-20
RU2727451C2 (ru) 2020-07-21
US10821161B2 (en) 2020-11-03
CA2969704C (en) 2023-05-02
EP4219530A1 (en) 2023-08-02
CN114085856A (zh) 2022-02-25
JP2017537627A (ja) 2017-12-21
AU2021200122A1 (en) 2021-03-18
IL290459B2 (en) 2023-11-01
KR20170090495A (ko) 2017-08-07
AU2015357485B2 (en) 2020-10-15
US12497440B2 (en) 2025-12-16
MX2017007250A (es) 2018-02-16

Similar Documents

Publication Publication Date Title
MX384964B (es) Células t modificadas en receptor de antígeno quimérico dirigo a cs1.
IL269578A (en) T cell receptors and immune therapy using the same against prame positive cancers
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12017501039A1 (en) Antibodies targeting g-protein coupled receptor and methods of use
IL270366A (en) Anti-CD3 binding sites and antibodies containing them, and methods of making and using them
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12016501894B1 (en) Anti-ox40 antibodies and methods of use
PL3183268T3 (pl) Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
SI3551221T1 (sl) Novi T-celični receptorji in imunska terapija z njihovo uporabo
PH12017501521A1 (en) Anti-dll3 chimeric antigen receptors and methods of use
PH12016501618A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
MX376026B (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
MX2017005797A (es) Receptores quimericos de antigeno anti-cldn y metodos de uso.
CA2904014C (en) Modified t lymphocytes having improved specificity
MX2017005553A (es) Terapia de combinacion para cancer.
MX374788B (es) Anticuerpos anti-tim3 y metodos de uso.
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
CR20150618A (es) Anticuerpos receptores de antitransferina y métodos de uso
SI3129470T1 (sl) Zdravljenje raka z uporabo antigenskega himernega receptorja proti-cd19
SI3227339T1 (sl) Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba
DK3119807T3 (da) Cd123-specifikke kimære antigenreceptorer til cancerimmunterapi
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
SG10201809628SA (en) Anti-ptk7 antibody-drug conjugates